Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mersil
- Development stage
- Unknown
- Lead developer
- Grand Medical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mersil is an oral dietary supplement developed by Grand Medical Group. It is formulated as capsules containing a combination of magnesium citrate, pyridoxine hydrochloride (vitamin B6), folic acid, and inulin. Mersil is indicated as a health supplement to support the cardiovascular and nervous systems, prevent magnesium deficiency (especially during pregnancy), and manage symptoms such as chronic physical and mental fatigue, irritability, sleep disorders, and myalgia. Magnesium acts as a vaso- and neuroprotective element, reducing neuronal excitability and regulating neuromuscular transmission, while vitamin B6 and folic acid support macronutrient metabolism, neurotransmitter synthesis, and cardiovascular health.
- Brand names
- Mersil
- Other names
- magnesium citrate + pyridoxine + folic acid + inulin
Beyond the preview
Go deeper on Mersil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mersil.